Sponsors (6)
The bill substantially strengthens U.S. influenza pandemic preparedness—accelerating vaccines, diagnostics, supply‑chains, and sustained funding—but does so with large recurring costs, potential diversion of other public‑health resources, implementation risks, and concerns about public trust, privacy, and oversight.
Patients (especially seniors and people with chronic conditions), healthcare workers, and the general public would get faster access to pandemic-capable influenza vaccines (goal: first doses within 12 weeks) and a coordinated push toward a universal influenza vaccine within a decade, improving early protection and reducing annual and pandemic flu burden.
Hospitals, public health agencies, and researchers would receive sustained, multi-year funding and strengthened stockpile support for R&D, countermeasures, and preparedness (including dedicated 'health defense' budget planning), enabling more reliable planning and readiness.
Domestic pharmaceutical and vaccine supply chains (ingredients, fill–finish, needles, manufacturing capacity) would be strengthened, reducing reliance on foreign suppliers and improving availability of vaccines and countermeasures during crises.
Taxpayers and federal budgets would face substantial new and recurring costs (hundreds of millions to over a billion annually) to fund R&D, stockpiles, demonstrations, and preparedness activities.
Prioritizing influenza countermeasures and related R&D and manufacturing support could divert limited federal and agency resources away from other public‑health needs and diseases.
Targeted communications, framing hesitancy as a security issue, expanded data-sharing, and new budget pathways risk eroding public trust, raising privacy concerns, and provoking perceptions of government persuasion among vaccine‑hesitant and minority communities.
Based on analysis of 6 sections of legislative text.
Sets national goals, new BARDA authority, reporting requirements, recurring appropriations, and a new "health defense operations" budget process to modernize influenza vaccines, diagnostics, and supply chains.
Official title: To protect against seasonal and pandemic influenza, and for other purposes.
Introduced April 22, 2026 by Richard Ray Larsen · Last progress April 22, 2026
Establishes national goals, funding, and new authorities to speed development, production, and distribution of influenza vaccines, diagnostics, therapeutics, and supply-chain capabilities to improve seasonal and pandemic readiness. It requires HHS and its agencies (ASPR, BARDA, NIH, CDC, FDA) to publish implementation plans, form public–private partnerships, run demonstration communication campaigns to increase vaccine confidence, and report annually to Congress through 2030. Creates recurring appropriations beginning in FY2027 for multiple influenza and public-health preparedness programs, authorizes a BARDA Pandemic Influenza Medical Countermeasures Program, sets timetables (first-dose within 12 weeks and a universal vaccine within 10 years), and establishes a new statutory “health defense operations” budget category with a required annual bypass-style budget submission to the President starting FY2028.